Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts

Journal of Bone and Mineral Research

Volumn 28, Issue 4, 2013, Pages 711-722

  Boyce, Brendan F ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

apoptosis; bone resorption; NF B; NFATc1; osteoblast; osteoclast; osteoclastogenic cytokine; RANKL

Indexed keywords

AUTOPHAGY PROTEIN 5; BETA3 INTEGRIN; BONE MORPHOGENETIC PROTEIN 2; CASPASE 3; CATHEPSIN K; CYCLOSPORIN A; DENOSUMAB; EPHRIN; FINGOLIMOD; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 3; INTERLEUKIN 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAXILLIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN CDC42; PROTEIN KINASE SYK; PROTEIN P100; SPHINGOSINE 1 PHOSPHATE; TACROLIMUS; TALIN; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VINCULIN;

ALBERS SCHOENBERG DISEASE; ARTHRITIS; B LYMPHOCYTE; CELL ADHESION; CELL DIFFERENTIATION; CELL LINEAGE; CELL MATURATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; DENDRITIC CELL; DISEASE SEVERITY; DOWN REGULATION; ENCHONDRAL OSSIFICATION; ERYTHROCYTE; GENE DELETION; GENE MUTATION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; MUTATION; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; PATHOLOGY; PROTEIN BINDING; PROTEIN EXPRESSION; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; T LYMPHOCYTE; ANIMAL; BONE DEVELOPMENT; BONE REMODELING; DRUG THERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANIMALS; BONE REMODELING; BONE RESORPTION; HUMANS; MOLECULAR TARGETED THERAPY; OSTEOCLASTS; OSTEOGENESIS;

EID: 84875306158     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1885     Document Type: Review

References (139)

1. Seeman E., Bone modeling and remodeling. Crit Rev Eukaryot Gene Expr. 2009; 19 (3): 219-33.
2. Eriksen EF., Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord. 2010; 11 (4): 219-27.
3. Henriksen K, Bollerslev J, Everts V, Karsdal MA., Osteoclast activity and subtypes as a function of physiology and pathology-implications for future treatments of osteoporosis. Endocr Rev. 2011; 32 (1): 31-63.
4. Muto A, Mizoguchi T, Udagawa N, Ito S, Kawahara I, Abiko Y, Arai A, Harada S, Kobayashi Y, Nakamichi Y, Penninger JM, Noguchi T, Takahashi N., Lineage-committed osteoclast precursors circulate in blood and settle down into bone. J Bone Miner Res. 2011; 26 (2): 2978-90.
5. Boyce BF, Rosenberg E, de Papp AE, Duong le T., The osteoclast, bone remodelling and treatment of metabolic bone disease. Eur J Clin Invest. 2012; 42 (12): 1332-41.
6. McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK, Lewiecki EM., Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013 Jan; 126 (1): 13-20.
7. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C., Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011; 377 (9768): 813-22.
8. Karsenty G, Wagner EF., Reaching a genetic and molecular understanding of skeletal development. Dev Cell. 2002; 2 (4): 389-406.
9. Boyce BF, Yao Z, Xing L., Osteoclasts have multiple roles in bone in addition to bone resorption. Crit Rev Eukaryot Gene Expr. 2009; 19 (3): 171-80.
10. Boyce BF, Schwarz EM, Xing L., Osteoclast precursors: cytokine-stimulated immunomodulators of inflammatory bone disease. Curr Opin Rheumatol. 2006; 18 (4): 427-32.
11. Steingrimsson E, Tessarollo L, Pathak B, Hou L, Arnheiter H, Copeland NG, et al. Mitf and Tfe3, two members of the Mitf-Tfe family of bHLH-Zip transcription factors, have important but functionally redundant roles in osteoclast development. Proc Natl Acad Sci U S A. 2002; 99 (7): 4477-82.
12. Mellis DJ, Itzstein C, Helfrich MH, Crockett JC., The skeleton: a multi-functional complex organ: the role of key signalling pathways in osteoclast differentiation and in bone resorption. J Endocrinol. 2011; 211 (2): 131-43.
13. Del Fattore A, Cappariello A, Teti A., Genetics, pathogenesis and complications of osteopetrosis. Bone. 2008; 42 (1): 19-29.
14. 3 and macrophage colony-stimulating factor: partners in osteoclast biology. Immunol Rev. 2005; 208: 88-105.
15. Pacifici R., Role of T cells in ovariectomy induced bone loss-revisited. J Bone Miner Res. 2012; 27 (2): 231-9.
16. Li P, Schwarz EM, O'Keefe RJ, Ma L, Boyce BF, Xing L., RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. J Bone Miner Res. 2004; 19 (2): 207-13.
17. Xing L, Bushnell TP, Carlson L, Tai Z, Tondravi M, Siebenlist U, Young F, Boyce BF., NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J Bone Miner Res. 2002; 17 (7): 1200-10.
18. Wang ZQ, Ovitt C, Grigoriadis AE, Mohle-Steinlein U, Ruther U, Wagner EF., Bone and haematopoietic defects in mice lacking c-fos. Nature. 1992; 360 (6406): 741-5.
19. Miller PD., A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis. Ther Adv Musculoskelet Dis. 2011; 3 (6): 271-82.
20. Masuyama R, Stockmans I, Torrekens S, Van Looveren R, Maes C, Carmeliet P, Bouillon R, Carmeliet G., Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest. 2006; 116 (12): 3150-9.
21. Usui M, Xing L, Drissi H, Zuscik M, O'Keefe R, Chen D, Boyce BF., Murine and chicken chondrocytes regulate osteoclastogenesis by producing RANKL in response to BMP2. J Bone Miner Res. 2008; 23 (3): 314-25.
22. Wang B, Jin H-T, Tang D, Zhu M, Boyce BF, Chen D., β-Catenin controls osteoclast formation through regulation of OPG and RANKL expression in chondrocytes. Poster session presented at: ASBMR 2010 Annual Meeting; 2010 Oct 15-19; Toronto, ON, Canada. Abstract available from: http://www.asbmr.org/ Meetings/AnnualMeeting/AbstractDetail.aspx?aid=e50da1f4-654e-4e5d-8b5b- eaef42410721/.
23. Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, Bonewald LF, Kodama T, Wutz A, Wagner EF, Penninger JM, Takayanagi H., Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011; 17 (10): 1231-4.
24. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA., Matrix-embedded cells control osteoclast formation. Nat Med. 2011; 17 (10): 1235-41.
25. Tatsumi S, Ishii K, Amizuka N, Li M, Kobayashi T, Kohno K, Ito M, Takeshita S, Ikeda K., Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab. 2007; 5 (6): 464-75.
26. Boyce BF, Xing L., Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008; 473 (2): 139-46.
27. Wada T, Nakashima T, Hiroshi N, Penninger JM., RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006; 12 (1): 17-25.
28. Boyle WJ, Simonet WS, Lacey DL., Osteoclast differentiation and activation. Nature. 2003; 423 (6937): 337-42.
29. Boyce BF, Yao Z, Xing L., Functions of nuclear factor kappaB in bone. Ann N Y Acad Sci. 2010; 1192: 367-75.
30. DiDonato JA, Mercurio F, Karin M., NF-kappaB and the link between inflammation and cancer. Immunol Rev. 2012; 246 (1): 379-400.
31. Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, Leonardi A, Tran T, Boyce BF, Siebenlist U., Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev. 1997; 11 (24): 3482-96.
32. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R., Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med. 1997; 3 (11): 1285-9.
33. Yamashita T, Yao Z, Li F, Zhang Q, Badell IR, Schwarz EM, Takeshita S, Wagner EF, Noda M, Matsuo K, Xing L, Boyce BF., NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem. 2007; 282 (25): 18245-53.
34. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T., Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002; 3 (6): 889-901.
35. Zhao B, Ivashkiv LB., Negative regulation of osteoclastogenesis and bone resorption by cytokines and transcriptional repressors. Arthritis Res Ther. 2011; 13 (4): 234.
36. Novack DV., Role of NF-kappaB in the skeleton. Cell Res. 2011; 21 (1): 169-82.
37. Vaira S, Alhawagri M, Anwisye I, Kitaura H, Faccio R, Novack DV., RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. J Clin Invest. 2008; 118 (6): 2088-97.
38. Otero JE, Dai S, Alhawagri MA, Darwech I, Abu-Amer Y., IKKbeta activation is sufficient for RANK-independent osteoclast differentiation and osteolysis. J Bone Miner Res. 2010; 25 (6): 1282-94.
39. Hacker H, Tseng PH, Karin M., Expanding TRAF function: TRAF3 as a tri-faced immune regulator. Nat Rev Immunol. 2011; 11 (7): 457-68.
40. Yao Z, Xing L, Boyce BF., NF-kappaB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism. J Clin Invest. 2009; 119 (10): 3024-34.
41. Jimi E, Aoki K, Saito H, D'Acquisto F, May MJ, Nakamura I, Sudo T, Kojima T, Okamoto F, Fukushima H, Okabe K, Ohya K, Ghosh S., Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med. 2004; 10 (6): 617-24.
42. Hogan PG, Chen L, Nardone J, Rao A., Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev. 2003; 17 (18): 2205-32.
43. Takayanagi H., Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007; 7 (4): 292-304.
44. Nakashima T, Hayashi M, Takayanagi H., New insights into osteoclastogenic signaling mechanisms. Trends Endocrinol Metab. 2012; 23 (11): 582-90.
45. Koga T, Matsui Y, Asagiri M, Kodama T, de Crombrugghe B, Nakashima K, Takayanagi H., NFAT and Osterix cooperatively regulate bone formation. Nat Med. 2005; 11 (8): 880-5.
46. Barrow AD, Raynal N, Andersen TL, Slatter DA, Bihan D, Pugh N, Cella M, Kim T, Rho J, Negishi-Koga T, Delaisse JM, Takayanagi H, Lorenzo J, Colonna M, Farndale RW, Choi Y, Trowsdale J., OSCAR is a collagen receptor that costimulates osteoclastogenesis in DAP12-deficient humans and mice. J Clin Invest. 2011; 121 (9): 3505-16.
47. Asagiri M, Takayanagi H., The molecular understanding of osteoclast differentiation. Bone. 2007; 40 (2): 251-64.
48. Crotti TN, Dharmapatni AA, Alias E, Zannettino AC, Smith MD, Haynes DR., The immunoreceptor tyrosine-based activation motif (ITAM) -related factors are increased in synovial tissue and vasculature of rheumatoid arthritic joints. Arthritis Res Ther. 2012; 14 (6): R245.
49. Rho J, Takami M, Choi Y., Osteoimmunology: interactions of the immune and skeletal systems. Mol Cell. 2004; 17 (1): 1-9.
50. Zaiss MM, Axmann R, Zwerina J, Polzer K, Guckel E, Skapenko A, Schulze-Koops H, Horwood N, Cope A, Schett G., Treg cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum. 2007; 56 (12): 4104-12.
51. Okamoto K, Takayanagi H., Regulation of bone by the adaptive immune system in arthritis. Arthritis Res Ther. 2011; 13 (3): 219.
52. Takayanagi H., New developments in osteoimmunology. Nat Rev Rheumatol. 2012; 8 (11): 684-689.
53. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takayanagi H., Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med. 2006; 203 (12): 2673-82.
54. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T., IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 1999; 103 (9): 1345-52.
55. Hueber AJ, Asquith DL, Miller AM, Reilly J, Kerr S, Leipe J, Melendez AJ, McInnes IB., Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol. 2010; 184 (7): 3336-40.
56. Adamopoulos IE, Chao CC, Geissler R, Laface D, Blumenschein W, Iwakura Y, McClanahan T, Bowman EP., Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors. Arthritis Res Ther. 2010; 12 (1): R29.
57. Charles JF, Hsu LY, Niemi EC, Weiss A, Aliprantis AO, Nakamura MC., Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function. J Clin Invest. 2012; 122 (12): 4592-605.
58. Schett G, David JP., The multiple faces of autoimmune-mediated bone loss. Nat Rev Endocrinol. 2010; 6 (12): 698-706.
59. Pacifici R., The immune system and bone. Arch Biochem Biophys. 2010; 503 (1): 41-53.
60. Li H, Hong S, Qian J, Zheng Y, Yang J, Yi Q., Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells. Blood. 2010; 116 (2): 210-7.
61. Grassi F, Manferdini C, Cattini L, Piacentini A, Gabusi E, Facchini A, Lisignoli G., T cell suppression by osteoclasts in vitro. J Cell Physiol. 2011; 226 (4): 982-90.
62. Sobacchi C, Frattini A, Guerrini MM, Abinun M, Pangrazio A, Susani L, Bredius R, Mancini G, Cant A, Bishop N, Grabowski P, Del Fattore A, Messina C, Errigo G, Coxon FP, Scott DI, Teti A, Rogers MJ, Vezzoni P, Villa A, Helfrich MH., Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet. 2007; 39 (8): 960-2.
63. Guerrini MM, Sobacchi C, Cassani B, Abinun M, Kilic SS, Pangrazio A, Moratto D, Mazzolari E, Clayton-Smith J, Orchard P, Coxon FP, Helfrich MH, Crockett JC, Mellis D, Vellodi A, Tezcan I, Notarangelo LD, Rogers MJ, Vezzoni P, Villa A, Frattini A., Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet. 2008; 83 (1): 64-76.
64. Perlot T, Penninger JM., Development and function of murine B cells lacking RANK. J Immunol. 2012; 188 (3): 1201-5.
65. Crockett JC, Mellis DJ, Scott DI, Helfrich MH., New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis. Osteoporos Int. 2011; 22 (1): 1-20.
66. Cundy T, Reid IR., Paget's disease of bone. Clin Biochem. 2012; 45 (1-2): 43-8.
67. Andersen TL, Sondergaard TE, Skorzynska KE, Dagnaes-Hansen F, Plesner TL, Hauge EM, Plesner T, Delaisse JM., A physical mechanism for coupling bone resorption and formation in adult human bone. Am J Pathol. 2009; 174 (1): 239-47.
68. Vaananen K., Mechanism of osteoclast mediated bone resorption-rationale for the design of new therapeutics. Adv Drug Deliv Rev. 2005; 57 (7): 959-71.
69. Zhang Q, Guo R, Schwarz EM, Boyce BF, Xing L., TNF inhibits production of stromal cell-derived factor 1 by bone stromal cells and increases osteoclast precursor mobilization from bone marrow to peripheral blood. Arthritis Res Ther. 2008; 10 (2): R37.
70. Li P, Schwarz EM, O'Keefe RJ, Ma L, Looney RJ, Ritchlin CT, Boyce BF, Xing L., Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice. Arthritis Rheum. 2004; 50 (1): 265-76.
71. Kikuta J, Iwai K, Saeki Y, Ishii M., S1P-targeted therapy for elderly rheumatoid arthritis patients with osteoporosis. Rheumatol Int. 2011; 31 (7): 967-9.
72. Chambers TJ, Fuller K., How are osteoclasts induced to resorb bone?. Ann N Y Acad Sci. 2011; 1240: 1-6.
73. Bonewald LF., The amazing osteocyte. J Bone Miner Res. 2011; 26 (2): 229-38.
74. Saltel F, Chabadel A, Bonnelye E, Jurdic P., Actin cytoskeletal organisation in osteoclasts: a model to decipher transmigration and matrix degradation. Eur J Cell Biol. 2008; 87 (8-9): 459-68.
75. Teitelbaum SL, Ross FP., Genetic regulation of osteoclast development and function. Nat Rev Genet. 2003; 4 (8): 638-49.
76. Schmidt S, Nakchbandi I, Ruppert R, Kawelke N, Hess MW, Pfaller K, Jurdic P, Fässler R, Moser M., Kindlin-3-mediated signaling from multiple integrin classes is required for osteoclast-mediated bone resorption. J Cell Biol. 2011; 192 (5): 883-97.
77. Malinin NL, Zhang L, Choi J, Ciocea A, Razorenova O, Ma YQ, Podrez EA, Tosi M, Lennon DP, Caplan AI, Shurin SB, Plow EF, Byzova TV., A point mutation in KINDLIN3 ablates activation of three integrin subfamilies in humans. Nat Med. 2009; 15 (3): 313-8.
78. Teitelbaum SL., The osteoclast and its unique cytoskeleton. Ann N Y Acad Sci. 2011; 1240: 14-7.
79. Boyce BF, Yoneda T, Lowe C, Soriano P, Mundy GR., Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest. 1992; 90 (4): 1622-7.
80. DeSelm CJ, Miller BC, Zou W, Beatty WL, van Meel E, Takahata Y, Klumperman J, Tooze SA, Teitelbaum SL, Virgin HW., Autophagy proteins regulate the secretory component of osteoclastic bone resorption. Dev Cell. 2011; 21 (5): 966-74.
81. Hocking LJ, Whitehouse C, Helfrich MH., Autophagy: a new player in skeletal maintenance?. J Bone Miner Res. 2012; 27 (7): 1439-47.
82. Zhao H, Ito Y, Chappel J, Andrews NW, Teitelbaum SL, Ross FP., Synaptotagmin VII regulates bone remodeling by modulating osteoclast and osteoblast secretion. Dev Cell. 2008; 14 (6): 914-25.
83. Boyce B, Xing L., Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data. Clin Investig (Lond). 2011; 1 (12): 1695-706.
84. Wong BR, Besser D, Kim N, Arron JR, Vologodskaia M, Hanafusa H, Choi Y., TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell. 1999; 4 (6): 1041-9.
85. Yagi M, Miyamoto T, Sawatani Y, Iwamoto K, Hosogane N, Fujita N, Morita K, Ninomiya K, Suzuki T, Miyamoto K, Oike Y, Takeya M, Toyama Y, Suda T., DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med. 2005; 202 (3): 345-51.
86. Lee SH, Rho J, Jeong D, Sul JY, Kim T, Kim N, Kang JS, Miyamoto T, Suda T, Lee SK, Pignolo RJ, Koczon-Jaremko B, Lorenzo J, Choi Y., v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat Med. 2006; 12 (12): 1403-9.
87. Sharma SM, Bronisz A, Hu R, Patel K, Mansky KC, Sif S, Ostrowski MC., MITF and PU.1 recruit p38 MAPK and NFATc1 to target genes during osteoclast differentiation. J Biol Chem. 2007; 282 (21): 15921-9.
88. Yagi M, Ninomiya K, Fujita N, Suzuki T, Iwasaki R, Morita K, Hosogane N, Matsuo K, Toyama Y, Suda T, Miyamoto T., Induction of DC-STAMP by alternative activation and downstream signaling mechanisms. J Bone Miner Res. 2007; 22 (7): 992-1001.
89. Fujita K, Iwasaki M, Ochi H, Fukuda T, Ma C, Miyamoto T, Takitani K, Negishi-Koga T, Sunamura S, Kodama T, Takayanagi H, Tamai H, Kato S, Arai H, Shinomiya K, Itoh H, Okawa A, Takeda S., Vitamin E decreases bone mass by stimulating osteoclast fusion. Nat Med. 2012; 18 (4): 589-94.
90. Van Wesenbeeck L, Odgren PR, Coxon FP, Frattini A, Moens P, Perdu B, MacKay CA, Van Hul E, Timmermans JP, Vanhoenacker F, Jacobs R, Peruzzi B, Teti A, Helfrich MH, Rogers MJ, Villa A, Van Hul W., Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. J Clin Invest. 2007; 117 (4): 919-30.
91. Tolar J, Teitelbaum SL, Orchard PJ., Osteopetrosis. N Engl J Med. 2004; 351 (27): 2839-49.
92. Stoch SA, Zajic S, Stone JA, Miller DL, van Bortel L, Lasseter KC, et al. Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics-results from single oral dose studies in healthy volunteers. Br J Clin Pharmacol. Epub. 2012 Sep 26. DOI: 10.1111/j.1365-2125.2012.04471.x.
93. Williams SC., Potential first-in-class osteoporosis drug speeds through trials. Nat Med. 2012; 18 (8): 1158.
94. Boonen S, Rosenberg E, Claessens F, Vanderschueren D, Papapoulos S., Inhibition of cathepsin K for treatment of osteoporosis. Curr Osteoporos Rep. 2012; 10 (1): 73-73-9.
95. Kearns AE, Khosla S, Kostenuik PJ., Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2008; 29 (2): 155-92.
96. Hill TP, Spater D, Taketo MM, Birchmeier W, Hartmann C., Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell. 2005; 8 (5): 727-38.
97. Maeda K, Kobayashi Y, Udagawa N, Uehara S, Ishihara A, Mizoguchi T, Kikuchi Y, Takada I, Kato S, Kani S, Nishita M, Marumo K, Martin TJ, Minami Y, Takahashi N., Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat Med. 2012; 18 (3): 405-12.
98. Bai S, Kopan R, Zou W, Hilton MJ, Ong CT, Long F, Ross FP, Teitelbaum SL., NOTCH1 regulates osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblast lineage cells. J Biol Chem. 2008; 283 (10): 6509-18.
99. Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, Mumm S., Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med. 2002; 347 (3): 175-84.
100. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS., osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998; 12 (9): 1260-8.
101. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, Yokochi T, Oda H, Nakamura K, Ida N, Wagner EF, Taniguchi T., RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature. 2002; 416 (6882): 744-9.
102. Davy A, Soriano P., Ephrin signaling in vivo: look both ways. Dev Dyn. 2005; 232 (1): 1-10.
103. Tran TS, Kolodkin AL, Bharadwaj R., Semaphorin regulation of cellular morphology. Ann Rev Cell Dev Biol. 2007; 23: 263-92.
104. Suzuki K, Kumanogoh A, Kikutani H., Semaphorins and their receptors in immune cell interactions. Nat Immunol. 2008; 9 (1): 17-23.
105. Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, Suda T, Matsuo K., Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab. 2006; 4 (2): 111-21.
106. Matsuo K, Otaki N., Bone cell interactions through Eph/ephrin: bone modeling, remodeling and associated diseases. Cell Adh Migr. 2012; 6 (2): 148-56.
107. Kang S, Kumanogoh A., Semaphorins in bone development, homeostasis, and disease. Semin Cell Dev Biol. Epub. 2012 Sep 27. DOI: 10.1016/j.semcdb.2012.09. 008.
108. Morrissey C, True LD, Roudier MP, Coleman IM, Hawley S, Nelson PS, Coleman R, Wang YC, Corey E, Lange PH, Higano CS, Vessella RL., Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin Exp Metastasis. 2008; 25 (4): 377-88.
109. Guenther R, Krenn V, Morawietz L, Dankof A, Melcher I, Schaser KD, Kasper HU, Kuban RJ, Ungethüm U, Sers C., Giant cell tumors of the bone: molecular profiling and expression analysis of Ephrin A1 receptor, Claudin 7, CD52, FGFR3 and AMFR. Pathol Res Pract. 2005; 201 (10): 649-63.
110. Hayashi M, Nakashima T, Taniguchi M, Kodama T, Kumanogoh A, Takayanagi H., Osteoprotection by semaphorin 3A. Nature. 2012; 485 (7396): 69-74.
111. Negishi-Koga T, Shinohara M, Komatsu N, Bito H, Kodama T, Friedel RH, Takayanagi H., Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med. 2011; 17 (11): 1473-80.
112. Miyauchi Y, Ninomiya K, Miyamoto H, Sakamoto A, Iwasaki R, Hoshi H, Miyamoto K, Hao W, Yoshida S, Morioka H, Chiba K, Kato S, Tokuhisa T, Saitou M, Toyama Y, Suda T, Miyamoto T., The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis. J Exp Med. 2010; 207 (4): 751-62.
113. Mahoney DJ, Swales C, Athanasou NA, Bombardieri M, Pitzalis C, Kliskey K, Sharif M, Day AJ, Milner CM, Sabokbar A., TSG-6 inhibits osteoclast activity via an autocrine mechanism and is functionally synergistic with osteoprotegerin. Arthritis Rheum. 2011; 63 (4): 1034-43.
114. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T., T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature. 2000; 408 (6812): 600-5.
115. Mori Y, Tsuji S, Inui M, Sakamoto Y, Endo S, Ito Y, Fujimura S, Koga T, Nakamura A, Takayanagi H, Itoi E, Takai T., Inhibitory immunoglobulin-like receptors LILRB and PIR-B negatively regulate osteoclast development. J Immunol. 2008; 181 (7): 4742-51.
116. Chiu YH, Mensah KA, Schwarz EM, Ju Y, Takahata M, Feng C, McMahon LA, Hicks DG, Panepento B, Keng PC, Ritchlin CT., Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP). J Bone Miner Res. 2012 Jan; 27 (1): 79-92.
117. Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF., Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med. 1996; 2 (10): 1132-6.
118. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, Takaoka K, Martin TJ, Chambon P, Kato S., Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell. 2007; 130 (5): 811-23.
119. Imai Y, Youn MY, Kondoh S, Nakamura T, Kouzmenko A, Matsumoto T, Takada I, Takaoka K, Kato S., Estrogens maintain bone mass by regulating expression of genes controlling function and life span in mature osteoclasts. Ann N Y Acad Sci. 2009; 1173 (Suppl 1): E31-9.
120. Cicek M, Vrabel A, Sturchio C, Pederson L, Hawse JR, Subramaniam M, Spelsberg TC, Oursler MJ., TGF-β inducible early gene 1 regulates osteoclast differentiation and survival by mediating the NFATc1, AKT, and MEK/ERK signaling pathways. PloS One. 2011; 6 (3): e17522.
121. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF., Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995; 10 (10): 1478-87.
122. Rogers MJ, Crockett JC, Coxon FP, Monkkonen J., Biochemical and molecular mechanisms of action of bisphosphonates. Bone. 2011; 49 (1): 34-41.
123. Reszka AA, Halasy-Nagy JM, Masarachia PJ, Rodan GA., Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem. 1999; 274 (49): 34967-73.
124. Matsumoto T, Nagase Y, Iwasawa M, Yasui T, Masuda H, Kadono Y, Nakamura K, Tanaka S., Distinguishing the proapoptotic and antiresorptive functions of risedronate in murine osteoclasts: role of the Akt pathway and the ERK/Bim axis. Arthritis Rheum. 2011; 63 (12): 3908-17.
125. Russell RG., Bisphosphonates: the first 40 years. Bone. 2011; 49 (1): 2-19.
126. Lodder MC, Van Pelt PA, Lems WF, Kostense PJ, Koks CH, Dijkmans BA., Effects of high dose IV pamidronate on disease activity and bone metabolism in patients with active RA: a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2003; 30 (9): 2080-1.
127. Valleala H, Laasonen L, Koivula MK, Mandelin J, Friman C, Risteli J, Konttinen YT., Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease. J Rheumatol. 2003; 30 (3): 468-73.
128. Zhang Q, Badell IR, Schwarz EM, Boulukos KE, Yao Z, Boyce BF, Xing L., Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2. Arthritis Rheum. 2005; 52 (9): 2708-18.
129. Jia D, O'Brien CA, Stewart SA, Manolagas SC, Weinstein RS., Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology. 2006; 147 (12): 5592-9.
130. Hanley DA, Adachi JD, Bell A, Brown V., Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract. 2012; 66 (12): 1139-46.
131. Krum SA, Miranda-Carboni GA, Hauschka PV, Carroll JS, Lane TF, Freedman LP, Brown M., Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J. 2008; 27 (3): 535-45.
132. Parfitt AM, Mundy GR, Roodman GD, Hughes DE, Boyce BF., A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res. 1996; 11 (2): 150-9.
133. Lorget F, Kamel S, Mentaverri R, Wattel A, Naassila M, Maamer M, Brazier M., High extracellular calcium concentrations directly stimulate osteoclast apoptosis. Biochem Biophys Res Commun. 2000; 268 (3): 899-03.
134. Chamoux E, Houde N, L'Eriger K, Roux S., Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway. J Cell Physiol. 2008; 216 (2): 536-42.
135. Tanaka S, Miyazaki T, Fukuda A, Akiyama T, Kadono Y, Wakeyama H, Kono S, Hoshikawa S, Nakamura M, Ohshima Y, Hikita A, Nakamura I, Nakamura K., Molecular mechanism of the life and death of the osteoclast. Ann N Y Acad Sci. 2006; 1068: 180-6.
136. Tanaka S, Wakeyama H, Akiyama T, Takahashi K, Amano H, Nakayama KI, Nakamura K., Regulation of osteoclast apoptosis by Bcl-2 family protein Bim and Caspase-3. Adv Exp Med Biol. 2010; 658: 111-6.
137. Akiyama T, Bouillet P, Miyazaki T, Kadono Y, Chikuda H, Chung UI, Fukuda A, Hikita A, Seto H, Okada T, Inaba T, Sanjay A, Baron R, Kawaguchi H, Oda H, Nakamura K, Strasser A, Tanaka S., Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim. EMBO J. 2003; 22 (24): 6653-64.
138. Woo KM, Kim HM, Ko JS., Macrophage colony-stimulating factor promotes the survival of osteoclast precursors by up-regulating Bcl-X(L). Exp Mol Med. 2002; 34 (5): 340-6.
139. Iwasawa M, Miyazaki T, Nagase Y, Akiyama T, Kadono Y, Nakamura M, Oshima Y, Yasui T, Matsumoto T, Nakamura T, Kato S, Hennighausen L, Nakamura K, Tanaka S., The antiapoptotic protein Bcl-xL negatively regulates the bone-resorbing activity of osteoclasts in mice. J Clin Invest. 2009; 119 (10): 3149-59.